Literature DB >> 26967341

Clinical practice guidelines from the French College of Gynecologists and Obstetricians (CNGOF): benign breast tumors - short text.

Vincent Lavoué1, Xavier Fritel2, Martine Antoine3, Françoise Beltjens4, Sofiane Bendifallah5, Martine Boisserie-Lacroix6, Loic Boulanger7, Geoffroy Canlorbe8, Sophie Catteau-Jonard9, Nathalie Chabbert-Buffet10, Foucauld Chamming's11, Elisabeth Chéreau12, Jocelyne Chopier13, Charles Coutant14, Julie Demetz7, Nicolas Guilhen15, Raffaele Fauvet16, Olivier Kerdraon17, Enora Laas10, Guillaume Legendre18, Carole Mathelin19, Cédric Nadeau15, Isabelle Thomassin Naggara13, Charlotte Ngô20, Lobna Ouldamer21, Arash Rafii22, Marie-Noelle Roedlich23, Jérémy Seror24, Jean-Yves Séror25, Cyril Touboul26, Catherine Uzan27, Emile Daraï8.   

Abstract

Screening with breast ultrasound in combination with mammography is needed to investigate a clinical breast mass (Grade B), colored single-pore breast nipple discharge (Grade C), or mastitis (Grade C). The BI-RADS system is recommended for describing and classifying abnormal breast imaging findings. For a breast abscess, a percutaneous biopsy is recommended in the case of a mass or persistent symptoms (Grade C). For mastalgia, when breast imaging is normal, no MRI or breast biopsy is recommended (Grade C). Percutaneous biopsy is recommended for a BI-RADS category 4-5 mass (Grade B). For persistent erythematous nipple or atypical eczema lesions, a nipple biopsy is recommended (Grade C). For distortion and asymmetry, a vacuum core-needle biopsy is recommended due to the risk of underestimation by simple core-needle biopsy (Grade C). For BI-RADS category 4-5 microcalcifications without any ultrasound signal, a minimum 11-G vacuum core-needle biopsy is recommended (Grade B). In the absence of microcalcifications on radiography cores additional samples are recommended (Grade B). For atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, flat epithelial atypia, radial scar and mucocele with atypia, surgical excision is commonly recommended (Grade C). Expectant management is feasible after multidisciplinary consensus. For these lesions, when excision margins are not clear, no new excision is recommended except for LCIS characterized as pleomorphic or with necrosis (Grade C). For grade 1 phyllodes tumor, surgical resection with clear margins is recommended. For grade 2 phyllodes tumor, 10mm margins are recommended (Grade C). For papillary breast lesions without atypia, complete disappearance of the radiological signal is recommended (Grade C). For papillary breast lesions with atypia, complete surgical excision is recommended (Grade C).
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  BI-RADS classification; Benign breast tumor; Mammogram; Pathological examination; Ultrasound

Mesh:

Year:  2016        PMID: 26967341     DOI: 10.1016/j.ejogrb.2016.02.017

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  4 in total

1.  Re-excision or "wait and watch"-a prediction model in breast phyllodes tumors after surgery.

Authors:  Xue Chao; Xiaoyan Jin; Cui Tan; Peng Sun; Junwei Cui; Hui Hu; Qian Ouyang; Kai Chen; Wei Wu; Zhanghai He; Yan Nie; Herui Yao
Journal:  Ann Transl Med       Date:  2020-03

Review 2.  Papillary lesions of the breast.

Authors:  Janina Kulka; Lilla Madaras; Giuseppe Floris; Sigurd F Lax
Journal:  Virchows Arch       Date:  2021-11-03       Impact factor: 4.535

3.  Incidence of inflammatory breast cancer in patients with clinical inflammatory breast symptoms.

Authors:  Yohann Dabi; Lauren Darrigues; Kelly Pons; Mylène Mabille; Issam Abd Alsamad; Rana Mitri; Dounia Skalli; Bassam Haddad; Cyril Touboul
Journal:  PLoS One       Date:  2017-12-20       Impact factor: 3.240

4.  Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography.

Authors:  Marta Román; Javier Louro; Margarita Posso; Carmen Vidal; Xavier Bargalló; Ivonne Vázquez; María Jesús Quintana; Rodrigo Alcántara; Francina Saladié; Javier Del Riego; Lupe Peñalva; Maria Sala; Xavier Castells
Journal:  Int J Environ Res Public Health       Date:  2022-02-24       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.